A bio-pharmaceutical enterprise specializing in the R&D, production and sales of human vaccines.Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “OLYMVAX” or “the Company”) is a bio-pharmaceutical enterprise specializing in the R&D, production and sales of human vaccines. The Company was founded in 2009 with a registered capital of RMB 405,265,000 and was successfully listed on the SSE Science and Technology Innovation Board (Stock Code: 688319) on June 8, 2021. Since its establishment, the Company has been committed to providing consumers at home and abroad with safe, effective and high-quality human vaccine products, including the upgrade products of traditional vaccines developed to improve the quality of life of the people with broad market demand, and the innovative vaccine products with great future market potential, which are not yet met or urgently needed for disease control and prevention. Currently, it has been granted 62 Chinese invention patents, 2 US patents and 1 European patent.
Adhering to the business philosophy of “strengthening process management, focusing on continuous improvement, and pursuing the highest quality”, the Company aims to become an "internationally renowned and domestically leading" vaccine supplier. In terms of construction and management of pharmaceutical production workshops, the Company has built and managed them in accordance with the 2010 Version of Chinese GMP and with reference to the standards of developed countries in Europe and America, laying a solid foundation for its products to enter the international market. In the aspect of product development, the Company has established a well-developed research and development system, and two subsidiaries, Chongqing Yuanlun Biotechnology Co., Ltd. and Chengdu XENOMIX Biotechnology Co., Ltd., jointly implementing a dual-wheel drive strategy of leveraging the strengths of innovative vaccine development and traditional vaccine upgrading and a R&D strategy of laying equal stress on independent development and joint development. At present, the Company has 3 vaccine products launched and formed a product pipeline of “multi-product reserve, orderly stepping and key breakthrough”.
2009year
Established in77000㎡
Planned floor area440
Existing employees3
Marketed products
No matter what twists and turns and no matter what difficulties and obstacles are in the way of an enterprise’s birth and development, as long as there is stable faith and a consolidated goal, the enterprise will grow better and better and finally achieve success.
Since its founding, Olymvax always keeps to its original development orientation, taking scientific research and its related achievements transformation as its duty; taking “products that benefit mankind” and “becoming the leading enterprise in the industry” as its business goal. Olymvax has formed a development process supported by an outstanding and independent R&D ability, solid accumulation of technological innovation, farsighted product configuration and strict quality assurance system.
In the coming future, shouldering the holy mission of providing human beings with vaccines that are safer, better and more effective; upholding the principles of “honesty, dedication, innovation and transcendence”; adopting the world’s leading managerial technique, Olymvax will never cease to innovate and excell; Olymvax is comitted to becoming an internationally well-known, domestically leading supplier of vaccines.
Olymvax strives to provide a strong development platform for each employee, to give a stable return on investment to each investor, to make professional contributions to social progress and technical development. I believe that with the help and support of all Olymvax staff and cooperative partners, our goal will finally be achieved.
Olymvax management team consists of professional personnel who have years of experience in bio-pharmaceutical business and those who have backgrounds of security, finance, marketing and overseas work or study experience. They have an average work experience of over 20 years. The management team has both smart responsibility assignment and strong team work spirit. Thus, the efficient running and rapid development of Olymvax’s businesses can be ensured.
Jan
the Company was recognized as one of listed enterprises of "2022 Top 100 New Economy Companies in Sichuan Province".the Company was selected into Leading Technology List of "2022 Innovation China".
Mar
the Company has been included in the list of Shanghai-HongKong Stock Connect.
Apr
the Company was approved to establish the Sichuan Province Foreign Intellectual Property Guidance Station.
May
the Company was approved to establish the Sichuan Province Human Vaccine Engineering Technology Research Center.the Company signed Technology Transfer (Patent Right) Contract on Recombinant acinetobacter baumanni protein vaccine project.
Jun
the Company was awarded with 2023 Sichuan Province Industry Quality Benchmarking.the Company won the second prize of Sichuan Provincial Patent Award.the Company passed the review for "Specialized and Innovative" medium and small-sized enterprise of Sichuan Province.
Aug
the signing ceremony of Olymvax Chongqing Research Institute Project was successfully held in Shapingba District of Chongqing.
Oct
the Company was approved to establish Sichuan Province Postdoctoral Innovation and Practice Base.the Company was successfully re-identified as the National High-Tech Enterprise.the Company and China Rongtong Scientific Research Institute Group Co., Ltd. held the signing ceremony for Class 1.1 New Medicine Genetic Engineering - Pseudomonas Aeruginosa Vaccine Project initiated by Doctor Zou Quanming, Army Medical University.
Nov
the Company was recognized as Sichuan Province Enterprise for Intellectual Property Strength.the Company was awarded as the High-Tech Zone Bio-Vaccine Pilot Test Platform.Fan Shaowen was honored with the "Annual Entrepreneurial Pioneer Award for Chinese Listed Companies"; Wu Wei received the Sunshine President Secretary of "2023 China Star Fund and Listed Company Value Summit Forum".
Dec
the Company has been recognized as the human vaccine pilot test platform of Chengdu Olymvax.the Company was selected as "2023 Municipal Contract-Abiding and Creditworthy Enterprise" of Chengdu city.
Feb
Olymvax was awarded as "2021 Model Enterprise of Integrity”.
Apr
Successfully selected as constituents of the SSE Biology and Medicine Index (Index Code:000683).
Jun
The kick-off meeting for Phase III clinical trial of Class 1 New Drug rFSAV jointly developed by the company was successfully held.
Jul
Olymvax’s subsidiary Xenomix held a signing ceremony for Influenza vaccine(split virion), inactivated, quadrivalent(MDCK cell) project with Belling Bio.
Oct
Won the 2022 Annual National Intellectual Property Advantage Enterprise.
Nov
Successfully selected as constituents of the SSE STAR Growth Index (Index Code:000690).
Dec
Olymvax’s subsidiary Xenomix (as research institute) was settled in Chengdu Tianfu International Bio-town.Awarded the 2021 Listed company”Jinniu Science and Technology Innovation Award”.
Mar
MenAC Conjugate Vaccine was officially launched.
Jun
Listed on the SSE STAR MARKET (stock code: 688319).Awarded “Model Base for Talent Introduction of Chengdu”.
Jul
Registered capital increased to 405.265 million CNY.
Sep
Rated as “Sichuan Province Integrity Enterprise”.Adsorbed Tetanus Vaccine got the renew Application License.
Oct
Honored “2021 Chengdu Leading Listed Enterprise of Key Industries” .The Technology Center of the company is awared as” Sichuan Enterprise Technology Center”.
Jul
Chengdu Bacterial Vaccine Engineering Technology Research Center based in Olymvax was rated as a municipal level center.
Sep
Once again identified as National high-tech enterprises.Self-developed MenAC Conjugate Vaccine received Drug Clinical Trial Approval.
Dec
Passed the quality management system certification, complying with GB/T24001-2016 And GB/T29490-2013.
Jul
Identified as 2019 Chengdu Enterprise Technology Center.
Jun
Awarded as the “2018 Chengdu High-tech Zone Innovation and Entrepreneurship Star of the Future”.Co-developed Class 1 New Drug rFSAV entered phase II clinical trail.Passed the environmental management system certification, complying with GB/T24001-2016/ISO14001:2015.
Feb
Received the “Authentication Certificate of Intellectual property Management System”,complying with GB/T29490-2013.
Jan
Class 1 New Drug rFSAV got the clinical summary report of Phase I.
Dec
Successfully got the safety production standardization authentification.
Nov
MenAC Conjugate Vaccine was in the registration process for production.
Aug
Once again identified as National High-tech Enterprise.
Jul
Issued the GMP Certificate for Hib Conjugate Vaccine.
Jun
Adsorbed Tetanus Vaccine was officially launched.
May
Self-developed Hib Conjugate Vaccine was received Drug Registration Appproval.Registered capital increased to 205.68 million CNY.
Mar
Honored as “2016 Model Intelligent Manufacturing Enterprise” by the High-tech Zone Government.
Jan
MenAC-Hib(conjugate) Combined Vaccine received Drug Clinical Trial Approval.
Dec
Adsorbed Tetanus Vaccine get the GMP Certificate.
Oct
Adsorbed Tetanus Vaccine recieved Drug Registration License.
Jul
Cooperate with Australian Griffith University in R&D of Class 1 New Drug Group A Streptococcus Vaccine.
Feb
Registered capital increased to 189.02 million CNY.
Dec
Successfully obtained the renewed “Drug Production License”.
Sep
MenAC Conjugate Vaccine obtained Drug Clinical Trial Approval.Listed on China National Equities Exchange and Quotations Market, the stock is shortly named as “olymvax Biopharmaceuticals”(stock code:833577).
Jun
Acquired Chongqing Yuanlun Biotechnology Co., Ltd.Class 1 New Drug rFSAV, co-developed with the Third Military Medical University, was issued Drug Clinical Trial Approval Flle.
Apr
Registered capital increased to 158 million CNY.
Feb 2012
Registered capital increased to 100 million CNY.
Oct 2012
Stage I(39000㎡) Production Base completed and put into use.Adsorbed Tetanus Vaccine received Drug Clinical Trial Approval.
Apr 2013
Hib Conjugate Vaccine recieved Drug Clinical Trial Approval.
Oct 2014
Identified as National High-tech Enterprise.
Jul 2013
Registered capital increased to 138 million CNY.
Dec 2009
Founded and registered with capital of 50 million CNY.
Jul 2011
Issued the Drug Production License.
May 2010
R&D laboratory put into use.
Recently, SSE, SZSE and SEHK simultaneously announced the inclusion of more listed companies’ stocks into the Underlying Stock List of Northbound Trading Link, marking a further expansion of the interoperability range of stock market trading between Chinese Mainland and Hong Kong...
The Second Badminton Competition of the OLYMVAX Cup - “Hold Badminton Flying, Keep You and Me Moving”
2019-04-10
“Never Fade Charms, Keep Original Aspiration” - 2018 Appreciation and Spring Festival Meeting
2019-04-10
